Yunkang Group Full Year 2023 Earnings: Misses Expectations

31 Mar 2024

Simply Wall Street

Share on XTweet

Yunkang Group Full Year 2023 Earnings Misses Expectations

All figures shown in the chart above are for the trailing 12 month (TTM) period. Yunkang Group Revenues and Earnings Miss Expectations.

Yunkang Group (HKG:2325) Full Year 2023 Results

Key Financial Results

Revenue: CN¥891.5m (down 76% from FY 2022).
Net loss: CN¥102.3m (down by 127% from CN¥377.3m profit in FY 2022).
CN¥0.17 loss per share (down from CN¥0.66 profit in FY 2022).

revenue-and-expenses-breakdown — SEHK:2325 Revenue and Expenses Breakdown March 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Yunkang Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) was also behind analyst expectations.

The primary driver behind last 12 months revenue was the Southern China segment contributing a total revenue of CN¥732.1m (82% of total revenue). Notably, cost of sales worth CN¥565.7m amounted to 63% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥191.6m (44% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥7.52m. Explore how 2325's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Healthcare industry in Hong Kong.

Performance of the Hong Kong Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Yunkang Group's balance sheet.

Valuation is complex, but we're helping make it simple.

Find out whether Yunkang Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.